CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 147 enrolled
Drug / intervention
NVX-CoV2373 +1 morebiological
Likely dose
NVX-CoV2373 5 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05875701
NCT05875701Phase 3Completed
CompareCT.gov

A Phase 3 Study to Evaluate the Immunogenicity and Safety of Novavax COVID-19 Vaccine(s) as Second or Subsequent Booster After mRNA Vaccines in Individuals 18 to 49 Years of Age

Novavax·interventional·Posted May 25, 2023·Updated Jun 26, 2025

In Brief

A Phase 3 clinical trial evaluating NVX-CoV2373 and SARS-CoV-2 rS antigen/Matrix-M Adjuvant for COVID-19. Completed, enrolled 147 participants across 5 sites.

Detailed Summary

This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster doses following a series of primary and booster doses of authorized/approved mRNA vaccines followed by a single booster dose of NVX-CoV2373 in the Novavax 2019nCoV-307 study (NCT05463068).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202420252026
First PostedMay 25, 2023
Enrollment StartMar 28, 2023
Primary CompletionNov 11, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.1 years ago

Interventions

NVX-CoV2373biological

1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1

SARS-CoV-2 rS antigen/Matrix-M Adjuvantbiological

1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS antigen+ 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1